Research Topics
| Amy D KlionSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Eosinophilic myeloproliferative disordersAmy D Klion
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Hematology Am Soc Hematol Educ Program 2011:257-63. 2011....
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary reportAmy D Klion
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Allergy Clin Immunol 117:1292-302. 2006..Furthermore, the need for newer therapeutic strategies and novel drugs, as well as multicenter trials to assess all treatment modalities, was emphasized...- Familial eosinophilia: a benign disorder?Amy D Klion
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Blood 103:4050-5. 2004..These data suggest that, despite prolonged marked eosinophilia, FE can be distinguished from HES by a more benign clinical course that may be related to a relative lack of eosinophil activation... - Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndromeAmy D Klion
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Blood 103:2939-41. 2004..These data suggest that anti-IL-5 therapy may be useful in the treatment of HES irrespective of the underlying etiology, although the observed rebound eosinophilia and attenuation of response require further study... 
How I treat hypereosinophilic syndromesAmy D Klion
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Blood 114:3736-41. 2009..5 x 10(9)/L (1500/mm3) or higher and discusses the role of currently available therapeutic agents in the treatment of these patients...- Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion
Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
Blood 110:3552-6. 2007..This trial was registered at http://www.clinicaltrials.gov as no. NCT00044304... - Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapyPrincess U Ogbogu
National Institute of Allergy and Infectious Diseases, Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Allergy Clin Immunol 124:1319-25.e3. 2009..With the exception of a recent multicenter trial of mepolizumab (anti-IL-5 mAb), published therapeutic experience has been restricted to case reports and small case series... - Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndromeJamie Robyn
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
Br J Haematol 132:286-92. 2006..These results suggest that the mutation arises in a pluripotential haematopoietic progenitor cell capable of giving rise to multiple lineages. The basis for the preferential expansion of eosinophils and mast cells remains unclear... - Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndromeYae Jean Kim
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Am J Hematol 82:615-24. 2007..Eosinophilia defines a distinct subgroup of ALPS patients with increased serum IgE levels, increased numbers of PBL of multiple lineages, and higher mortality from infectious complications... - Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700Yae-Jean Kim
NIAID, NIH, Bethesda, MD 20892, USA
J Allergy Clin Immunol 114:1449-55. 2004..CONCLUSIONS: The rebound eosinophilia after SCH55700 treatment is a result of a serum factor that enhances eosinophil survival. Reversal of this effect by the addition of antibody to IL-5 suggests that this factor may be IL-5 itself... - Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeAmy D Klion
Bldg 4, Rm 126, National Institutes of Health, Bethesda, MD 20892
Blood 103:473-8. 2004..The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES... - KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entitiesIrina Maric
Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
J Allergy Clin Immunol 120:680-7. 2007..It is of paramount importance, however, to distinguish between these 2 groups of patients because of differences in clinical sequelae, prognoses, and selection of treatment... - IL-5 receptor α levels in patients with marked eosinophilia or mastocytosisTodd M Wilson
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
J Allergy Clin Immunol 128:1086-92.e1-3. 2011..Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor α (IL-5Rα) on eosinophils in vitro, little is known about soluble and surface IL-5Rα levels in vivo... - Molecular identification of Wolbachia from the filarial nematode Mansonella perstansPaul B Keiser
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Mol Biochem Parasitol 160:123-8. 2008.... - Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessAmy D Klion
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Blood 101:4660-6. 2003..In summary, elevated serum tryptase appears to be a sensitive marker of a myeloproliferative variant of HES that is characterized by tissue fibrosis, poor prognosis, and imatinib responsiveness... - Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-γ in filaria-malaria co-infectionSimon Metenou
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Eur J Immunol 42:641-50. 2012.... - Filariasis in travelers presenting to the GeoSentinel Surveillance NetworkEttie M Lipner
Office of Global Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
PLoS Negl Trop Dis 1:e88. 2007..The GeoSentinel Surveillance Network, a global network of medicine/travel clinics, was established in 1995 to detect morbidity trends among travelers... - Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstansPaul B Keiser
Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0425, USA
Am J Trop Med Hyg 69:331-5. 2003..bancrofti infection in this community, and that acute post-treatment reactions should not limit patient compliance in community-based programs to eliminate lymphatic filariasis... - Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infectionAmy D Klion
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Infect Dis 187:128-33. 2003..IgG4 antibodies to recombinant Ll-SXP-1 are a highly specific marker of L. loa infection and may be useful for the diagnostic evaluation of persons with filariasis of unclear etiology... - Rapid, novel, specific, high-throughput assay for diagnosis of Loa loa infectionPeter D Burbelo
Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, 4 Center Drive, Bethesda, Maryland 20892, USA
J Clin Microbiol 46:2298-304. 2008..These results suggest that LIPS (and the even more rapid test QLIPS) represents a major advance in the ability to diagnose L. loa infection and may have future applications for point-of-care diagnostics... - The role of eosinophils in host defense against helminth parasitesAmy D Klion
Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0425, USA
J Allergy Clin Immunol 113:30-7. 2004..This article will provide an overview of our current knowledge about eosinophils and their role, both protective and pathogenetic, in parasitic helminth infections... - Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infectionsSasisekhar Bennuru
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Am J Trop Med Hyg 83:884-90. 2010.... - Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infectionKawsar R Talaat
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland, USA
Pediatr Blood Cancer 53:1120-3. 2009..Thus, loss of SAP function can lead to dysregulated immune responses characterized by the uncontrolled expansion and activation of T cells independent of EBV infection... - Filaria-induced monocyte dysfunction and its reversal following treatmentRoshanak Tolouei Semnani
Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, 4 Center Drive, Room 4 126, National Institutes of Health, Bethesda, Maryland 20892, USA
Infect Immun 74:4409-17. 2006..These data suggest that the function and gene expression of monocytes in filaria-infected patients are altered but that this dysfunction is partially reversible following antifilarial treatment... - Approach to the therapy of hypereosinophilic syndromesAmy D Klion
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 4, Rm 126, 4 Center Drive, Bethesda, MD 20892, USA
Immunol Allergy Clin North Am 27:551-60. 2007..This article discusses current treatment modalities for myeloproliferative HES, idiopathic HES, and lymphocytic-variant HES... - Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndromeRichard M Stone
Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Semin Oncol 31:12-7. 2004..The efficacy of relatively low imatinib concentrations in HES, mediated by inhibition of FIP1L1-PDGFRalpha kinase activity, causally implicates FIP1L1-PDGFRA in the pathogenesis in certain HES patients... - Anti-interleukin-5 therapy for asthma and hypereosinophilic syndromeA Barry Kay
Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Guy Scadding Building, Dovehouse Street, London, SW3 6LY UK
Immunol Allergy Clin North Am 24:645-66, vii. 2004..This article discusses the rationale for the use of anti-IL-5 therapy in asthma and hypereosinophilic syndrome and summarizes the available clinical data on the use of anti-IL-5 to treat these disorders... - Treatment of patients with the hypereosinophilic syndrome with mepolizumabMarc E Rothenberg
Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
N Engl J Med 358:1215-28. 2008..Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity... - Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative diseaseCindy S Ma
Lymphocyte Differentiation Laboratory, Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
J Clin Invest 116:322-33. 2006..Production of affinity-matured IgM by IgMCD27 B cells may protect against pathogens to which a normal immune response is elicited in XLP patients...